Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Warner Chilcott Plc (WCRX), The Boeing Company (BA), Sequenom, Inc. (SQNM): Three Recent Upgrades You May Want to Ignore

Page 1 of 2

Warner Chilcott Plc (NASDAQ:WCRX)An analyst’s upgrade almost always causes a stock to trend higher. However, those gains can often be a value-trap. In this piece, I am looking at three such stocks; those that I believe are presenting a value trap to investors.

Avoid the Large Buyout Rumors

Warner Chilcott Plc (NASDAQ:WCRX) saw a slew of upgrades from firms Morgan Stanley, UBS, and CRT Capital, all of whom are buying the idea of a merger with Actavis. According to these firms, the average buyout price for WCRX is $23, yet Buckingham believes the deal could see a stock upwards of $30. In the last two days shares of Warner Chilcott Plc (NASDAQ:WCRX) has rallied more than 25%, thus making a $23 buyout price a premium of more than 50% from its May 9 close (when the deal was first reported).

Warner Chilcott Plc (NASDAQ:WCRX) has zero growth, has lost numerous drugs to generics, and has a debt-to-assets ratio that continues to rise by the quarter. Warner Chilcott Plc (NASDAQ:WCRX) was reportedly in the buyout market last year, and Actavis is the first company to show significant interest. Therefore, Warner Chilcott Plc (NASDAQ:WCRX) doesn’t really have any leverage. Now, I’m not suggesting that the merger won’t expand Actavis’ sales team, its presence, and expand its IP portfolio and pipeline, but it’s not worth a 50% premium to last Thursday’s close. In my opinion, I’d be careful, and would assume that most upside is priced into the stock. I would not buy on these upgrades.

A Great Company, But Not Deeply Valued

The Boeing Company (NYSE:BA) has seen massive YTD gains of more than 25% (after a flat year in 2012) despite a very public safety issue with its new Dreamliner. Much of its rally has been fundamental, but some has been induced by analysts who cover the stock. On Monday, Sterne Agee issued yet another bullish outlook, raising the stock’s price target from $100 to $120 due to its expectations of $18 billion in free cash flow over the next three years. Furthermore, the firm explains its $120 price target by saying that it expects The Boeing Company (NYSE:BA) to trade near the top of its historic range of 10-12 times free cash flow.

While these metrics may be correct, I am more concerned with the company’s metrics compared to the S&P 500 relative to economic growth (also called the 10-10-10 strategy detailed in my book). When I look at Boeing from this perspective, I don’t see a company that is incredibly cheap relative to the market. In fact, it is near fair value with a P/E ratio over 16 that is equal to the S&P 500, thus I don’t see the great value or discount suggested by Sterne Agee.

Need to See Margin Improvements Before Buying Into Hype

Sequenom, Inc. (NASDAQ:SQNM) has rallied 25% in the last five sessions following better-than-expected earnings and a bullish upgrade from Credit Suisse. According to the firm, risks stemming from its five-year agreement with Blue Cross and Blue Shield for the MaterniT21 PLUS test have diminished. The expectations for full-year tests have been erratic yet have recently settled around an estimated 150,000. However, after strong earnings, Credit Suisse is anticipating test sales of 175,000.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!